A detailed history of China Universal Asset Management Co., Ltd. transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 43,656 shares of RXRX stock, worth $319,561. This represents 0.06% of its overall portfolio holdings.

Number of Shares
43,656
Previous 43,656 -0.0%
Holding current value
$319,561
Previous $435,000 -0.0%
% of portfolio
0.06%
Previous 0.06%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

BUY
$9.13 - $15.52 $178,628 - $303,648
19,565 Added 81.21%
43,656 $435,000
Q4 2023

May 21, 2024

SELL
$5.09 - $10.79 $99,585 - $211,106
-19,565 Reduced 44.82%
24,091 $237,000
Q4 2023

Jan 23, 2024

BUY
$5.09 - $10.79 $95,966 - $203,434
18,854 Added 360.02%
24,091 $238,000
Q3 2023

May 21, 2024

BUY
$6.59 - $15.86 $18,564 - $44,677
2,817 Added 116.4%
5,237 $40,000
Q3 2023

Oct 30, 2023

BUY
$6.59 - $15.86 $18,564 - $44,677
2,817 Added 116.4%
5,237 $40,000
Q2 2023

May 21, 2024

SELL
$4.56 - $9.94 $296 - $646
-65 Reduced 2.62%
2,420 $18,000
Q2 2023

Jul 27, 2023

SELL
$4.56 - $9.94 $296 - $646
-65 Reduced 2.62%
2,420 $18,000
Q1 2023

May 21, 2024

BUY
$6.42 - $9.64 $4,102 - $6,159
639 Added 34.62%
2,485 $16,000
Q1 2023

Apr 27, 2023

BUY
$6.42 - $9.64 $4,102 - $6,159
639 Added 34.62%
2,485 $17,000
Q4 2022

May 21, 2024

SELL
$7.16 - $12.7 $299,359 - $530,987
-41,810 Reduced 95.77%
1,846 $14,000
Q4 2022

Jan 31, 2023

BUY
$7.16 - $12.7 $2,140 - $3,797
299 Added 19.33%
1,846 $14,000
Q3 2022

Oct 21, 2022

BUY
$7.83 - $13.6 $12,113 - $21,039
1,547 New
1,547 $16,000

Others Institutions Holding RXRX

About RECURSION PHARMACEUTICALS, INC.


  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.32B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.